Jason Duncan

This profile gathers the share dealings of Jason Duncan in Albireo Pharma, Inc., where the filings describe the role as senior executive. The record holds 15 filings, for trades running from 24 June 2021 to 2 March 2023.

On the market, this insider has only sold: 10 sales, €84k in total. The rest of the record consists of 3 share grants and 1 option exercise. 2023 to date brings no purchases and 2 sales.

Most recently, on 2 March 2023, the filings show a transaction in Albireo Pharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.